Genomic Signatures Associated with the Development, Progression, and Outcome of Prostate Cancer

被引：0
作者：
Prateek Mendiratta
Phillip G. Febbo
机构：
[1] Duke University,Institute for Genome Sciences and Policy
[2] Duke University Medical Center,Division of Medical Oncology, Department of Medicine
[3] Duke University Medical Center,Department of Molecular Genetics and Microbiology
来源：
Molecular Diagnosis & Therapy | 2007年 / 11卷
关键词：
Prostate Cancer; Docetaxel; Androgen Receptor; Everolimus; Localize Prostate Cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Prostate cancer remains a common cause of cancer death in men. Applications of new genomic technologies to the recent development of high-quality prostate cancer models in multiple contexts have added great molecular insight into the development of and progression to metastasis. Genomic analysis of DNA, RNA, and protein alterations allows for the global assessment of this disease and provides the molecular framework to improve risk classification, outcome prediction, and development of targeted therapies. The creation of expression profiles and signatures will allow the evaluation of cancer phenotypes and give insight into determining those with increased risk of cancer, identification of critical pathways involved in the development of cancer, prediction of disease outcome, and assessment of the response of cancer to established and novel therapies.
引用
收藏
页码：345 / 354
页数：9
相关论文
共 241 条
[1]  
Jemal A(2007)Cancer statistics, 2007 CA Cancer J Clin 57 43-66
[2]  
Siegel R(1941)Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate Cancer Res 1 293-7
[3]  
Ward E(2007)Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer: results from a prospective, population-based randomized controlled trial Eur Urol 51 659-64
[4]  
Huggins C(1996)Trends in prostate cancer survival in Sweden, 1960 through 1988: evidence of increasing diagnosis of nonlethal tumors J Natl Cancer Inst 88 1216-21
[5]  
Hodges CV(1996)Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search Science 274 1371-4
[6]  
Aus G(2004)The complex genetic epidemiology of prostate cancer Hum Mol Genet 1 Rl 03-21
[7]  
Bergdahl S(2000)Genetics of prostate cancer: too many loci, too few genes Am J Hum Genet 67 1367-75
[8]  
Lodding P(2002)Germline mutations in the ribonucleaseL gene in families showing linkage with HPC1 Nature genetics 30 181-4
[9]  
Helgesen F(2002)RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases Nat Genet 32 581-3
[10]  
Holmberg L(2006)Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant PLoS Pathog 2 e25-60
12345678910